Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riboflavin for Muscle Soreness in Ultramarathon Athletes
NCT05907850Phase 1Completed
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in delayed onset muscle soreness (DOMS) comparing Riboflavin Group with Placebo Group (2 arms). Primary endpoint: Muscle soreness measure for long stage of the ultramarathon. Started Jun 2023; status: completed.
02
Drugs
riboflavin
03
Conditions
delayed onset muscle soreness (DOMS)
Beyond the preview
Go deeper on NCT05907850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907850.